Endonovo Therapeutics annual debt-to-assets ratio
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Debt-to-Assets Ratio Growth & History (ENDV)
Endonovo Therapeutics's debt-to-assets ratio was 387.70 for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 387.70 | 376.61 | +3397.68% |
| 2023 | 2023-12-31 | 11.08 | 5.50 | +98.54% |
| 2022 | 2022-12-31 | 5.58 | 1.97 | +54.42% |
| 2021 | 2021-12-31 | 3.62 | 0.99 | +37.90% |
| 2020 | 2020-12-31 | 2.62 | 0.52 | +24.88% |
| 2019 | 2019-12-31 | 2.10 | 0.18 | +9.17% |
| 2018 | 2018-12-31 | 1.92 | 0.33 | +20.57% |
| 2017 | 2017-12-31 | 1.59 | −8.43 | −84.09% |
| 2016 | 2016-12-31 | 10.02 | 9.95 | +14220.70% |
| 2015 · Dec 31 | 2015-12-31 | 0.07 | −34.43 | −99.80% |
| 2014 | 2014-12-31 | 34.50 | — | — |
Endonovo Therapeutics quarterly debt-to-assets ratio
Q4.14
Q1.15
Q4.15
Q1.16
Q2.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 384.26 | — | — |
| Q1 2025 | 2025-03-31 | 387.37 | — | — |
| Q4 2024 | 2024-12-31 | 387.70 | — | — |
| Q3 2023 | 2023-09-30 | 8.69 | 3.68 | +73.39% |
| Q2 2023 | 2023-06-30 | 6.95 | 2.31 | +49.65% |
| Q1 2023 | 2023-03-31 | 5.76 | 1.70 | +42.06% |
| Q4 2022 | 2022-12-31 | 5.58 | 1.97 | +54.42% |
| Q3 2022 | 2022-09-30 | 5.01 | 1.82 | +56.92% |
| Q2 2022 | 2022-06-30 | 4.64 | 1.69 | +56.96% |
| Q1 2022 | 2022-03-31 | 4.05 | 1.34 | +49.44% |
| Q4 2021 | 2021-12-31 | 3.62 | 0.99 | +37.90% |
| Q3 2021 | 2021-09-30 | 3.19 | 0.92 | +40.28% |
| Q2 2021 | 2021-06-30 | 2.96 | 0.80 | +37.35% |
| Q1 2021 | 2021-03-31 | 2.71 | 0.74 | +37.32% |
| Q4 2020 | 2020-12-31 | 2.62 | 0.52 | +24.88% |
| Q3 2020 | 2020-09-30 | 2.28 | 0.09 | +4.23% |
| Q2 2020 | 2020-06-30 | 2.15 | 0.33 | +18.09% |
| Q1 2020 | 2020-03-31 | 1.97 | −0.01 | −0.59% |
| Q4 2019 | 2019-12-31 | 2.10 | 0.18 | +9.17% |
| Q3 2019 | 2019-09-30 | 2.18 | 0.40 | +22.27% |
| Q2 2019 | 2019-06-30 | 1.82 | 0.08 | +4.35% |
| Q1 2019 | 2019-03-31 | 1.99 | 0.35 | +21.64% |
| Q4 2018 | 2018-12-31 | 1.92 | 0.33 | +20.57% |
| Q3 2018 | 2018-09-30 | 1.79 | −20.93 | −92.14% |
| Q2 2018 | 2018-06-30 | 1.75 | −14.45 | −89.21% |
| Q1 2018 | 2018-03-31 | 1.63 | −6.18 | −79.10% |
| Q4 2017 | 2017-12-31 | 1.59 | −8.43 | −84.09% |
| Q3 2017 | 2017-09-30 | 22.72 | 15.62 | +219.84% |
| Q2 2017 | 2017-06-30 | 16.20 | −6.10 | −27.37% |
| Q1 2017 | 2017-03-31 | 7.81 | — | — |
| Q4 2016 | 2016-12-31 | 10.02 | 9.95 | +14220.70% |
| Q2 2016 | 2016-09-30 | 7.10 | — | — |
| Q1 2016 · Jun 30 | 2016-06-30 | 22.31 | — | — |
| Q4 2015 | 2015-12-31 | 0.07 | −34.43 | −99.80% |
| Q1 2015 | 2015-03-31 | 0.58 | — | — |
| Q4 2014 | 2014-12-31 | 34.50 | — | — |
Endonovo Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Endonovo Therapeutics's debt-to-assets ratio increased from 2.10 to 387.70, a change of 385.60. The latest reported quarter, Q2 2025, shows 384.26.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗